0000000001308054
AUTHOR
Rui Henrique
MicroRNA-30a-5pme: a novel diagnostic and prognostic biomarker for clear cell renal cell carcinoma in tissue and urine samples
Abstract Background The rising incidence of renal cell carcinomas (RCC) constitutes a significant challenge owing to risk of overtreatment. Because aberrant microRNA (miR) promoter methylation contributes to cancer development, we investigated whether altered miR-30a-5p expression associates with DNA promoter methylation and evaluated the usefulness as clear cell RCC (ccRCC) diagnostic and prognostic markers. Methods Genome-wide methylome and RNA sequencing data from a set of ccRCC and normal tissue samples from The Cancer Genome Atlas (TCGA) database were integrated to identify candidate CpG loci involved in cancer onset. MiR-30a-5p expression and promoter methylation were quantitatively a…
Circulating miR-30b-5p levels in plasma as a novel potential biomarker for early detection of breast cancer
Background Recently, microRNAs have been demonstrated to be potential non-invasive biomarkers for diagnosis, prognosis assessment or prediction of response to treatment in cancer. In this study, we evaluate the potential of miR-30b-5p as a biomarker for early diagnosis of breast cancer (BC) in tissue and plasma. Methods Expression of miR-30b-5p was determined in a series of 112 BC and 40 normal breast tissues. Circulating miR-30b-5p levels in plasma samples were determined in a discovery cohort of 38 BC patients and 40 healthy donors and in a validation cohort of 83 BC patients and 83 healthy volunteers. miR-30b-5p expression was measured by quantitative real-time PCR and receiver operating…
Identification of a Two-MicroRNA Signature in Plasma as a Novel Biomarker for Very Early Diagnosis of Breast Cancer
Simple Summary Breast cancer diagnosis at the initial stage of the disease considerably improves prognosis and survival rates. This retrospective study aimed to develop and validate a plasma microRNA signature as a non-invasive biomarker for early-stage breast cancer diagnosis. We confirmed in a testing cohort of 54 BC patients and 89 healthy volunteers the value of a signature based on miR-30b and miR-99a levels in plasma samples for stage I breast cancer detection. Furthermore, our results were blindly validated in a second cohort of 74 breast cancer and 74 healthy samples. The proposed microRNA signature presented high value as a fast, cost-effective, and non-invasive biomarker for early…
The Porto European Cancer Research Summit 2021.
Key stakeholders from the cancer research continuum met in May 2021 at the European Cancer Research Summit in Porto to discuss priorities and specific action points required for the successful implementation of the European Cancer Mission and Europe's Beating Cancer Plan (EBCP). Speakers presented a unified view about the need to establish high‐quality, networked infrastructures to decrease cancer incidence, increase the cure rate, improve patient's survival and quality of life, and deal with research and care inequalities across the European Union (EU). These infrastructures, featuring Comprehensive Cancer Centres (CCCs) as key components, will integrate care, prevention and research acros…
Additional file 4 of MicroRNA-30a-5pme: a novel diagnostic and prognostic biomarker for clear cell renal cell carcinoma in tissue and urine samples
Additional file 4 Supplementary Table 1. Univariable and multivariable analysis of clinicopathological and epigenetic variables in TCGA Cohort (OS and RFS). Supplementary Table 2. List of primers’ sequence for qMSP analysis. Supplementary Table 3. qMSP primers’ design within the methylated gene’s sequence. Supplementary Table 4. Cox univariable and multivariable analysis of clinicopathological and epigenetic variables in Cohort #1 (DFS). Supplementary Table 5. Cox univariable analysis of clinicopathological and epigenetic variables in Cohort #1 (DSS). Supplementary Table 6. Cox univariable and multivariable analysis of clinicopathological and epigenetic variables in Cohort #2 (MFS). Supplem…
Circulating miR-99a-5p Expression in Plasma: A Potential Biomarker for Early Diagnosis of Breast Cancer
MicroRNAs have emerged as new diagnostic and therapeutic biomarkers for breast cancer. Herein, we analysed miR-99a-5p expression levels in primary tumours and plasma of breast cancer patients to evaluate its usefulness as a minimally invasive diagnostic biomarker. MiR-99a-5p expression levels were determined by quantitative real-time PCR in three independent cohorts of patients: (I) Discovery cohort: breast cancer tissues (n = 103) and healthy breast tissues (n = 26)
Additional file 2 of MicroRNA-30a-5pme: a novel diagnostic and prognostic biomarker for clear cell renal cell carcinoma in tissue and urine samples
Additional file 2 Supplementary Figure S2. Prognostic value of stage and nuclear grade in Cohort #1. (A) Disease-free and (B) disease-specific Kaplan-Meier survival curves based on clinicopathological stage and nuclear grade (Log-rank test).
Additional file 1 of MicroRNA-30a-5pme: a novel diagnostic and prognostic biomarker for clear cell renal cell carcinoma in tissue and urine samples
Additional file 1 Supplementary Figure S1. Expression of miR-30a-5p according to clinicopathological variables in Cohort #1. Scatter plots of miR-30a-5p expression levels according to metastasis presentation, recurrence and Führman grade (Mann–Whitney U test).
Additional file 3 of MicroRNA-30a-5pme: a novel diagnostic and prognostic biomarker for clear cell renal cell carcinoma in tissue and urine samples
Additional file 3 Supplementary Figure S3. MiR-30a-5pme levels and prognostic value of stage and nuclear grade in Cohort #2 (A) Scatter plots of miR-30a-5pme levels according to pathological stage (Mann–Whitney U test); (B) Disease-specific and (C) Metastasis-free Kaplan-Meier survival curves based on clinicopathological stage and nuclear grade (Log-rank test).